OnKure Therapeutics (OKUR) Competitors $2.56 +0.06 (+2.19%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. FATE, CRBU, CRDL, KRRO, NKTX, IMRX, KYTX, UPXI, PLX, and BHSTShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Fate Therapeutics (FATE), Caribou Biosciences (CRBU), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), Nkarta (NKTX), Immuneering (IMRX), Kyverna Therapeutics (KYTX), Upexi (UPXI), Protalix BioTherapeutics (PLX), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Fate Therapeutics Caribou Biosciences Cardiol Therapeutics Korro Bio Nkarta Immuneering Kyverna Therapeutics Upexi Protalix BioTherapeutics BioHarvest Sciences OnKure Therapeutics (NASDAQ:OKUR) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Do institutionals & insiders hold more shares of OKUR or FATE? 91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, OKUR or FATE? OnKure Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.49Fate Therapeutics$13.63M9.46-$186.26M-$1.49-0.76 Does the media favor OKUR or FATE? In the previous week, Fate Therapeutics had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Fate Therapeutics' score of 0.44 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Overall Sentiment OnKure Therapeutics Very Positive Fate Therapeutics Neutral Which has more risk and volatility, OKUR or FATE? OnKure Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Do analysts rate OKUR or FATE? OnKure Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 1,160.56%. Fate Therapeutics has a consensus target price of $3.83, indicating a potential upside of 240.74%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is OKUR or FATE more profitable? OnKure Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -49.13% -45.72% Fate Therapeutics -1,318.93%-47.17%-34.60% SummaryOnKure Therapeutics beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.65M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.4920.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.337.718.185.63Net Income-$52.67M-$55.11M$3.23B$257.73M7 Day Performance0.59%0.68%-0.25%0.07%1 Month Performance-1.35%8.22%5.40%8.32%1 Year PerformanceN/A-2.64%26.35%13.78% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.5906 of 5 stars$2.57+2.2%$32.33+1,160.6%N/A$34.65MN/A-0.49N/AFATEFate Therapeutics3.6202 of 5 stars$1.06-5.4%$3.83+261.6%-71.0%$128.36M$13.63M-0.71550Gap UpCRBUCaribou Biosciences2.9088 of 5 stars$1.39+1.5%$8.50+511.5%-24.4%$127.42M$9.99M-0.86100Positive NewsCRDLCardiol Therapeutics2.4309 of 5 stars$1.45-5.8%$8.00+451.7%-39.4%$127.28MN/A-4.2620Positive NewsKRROKorro Bio1.5125 of 5 stars$12.58-5.8%$102.43+714.2%-74.3%$125.36M$2.27M-1.3370NKTXNkarta1.8141 of 5 stars$1.69-3.4%$14.33+748.1%-74.1%$124.18MN/A-1.12140Positive NewsIMRXImmuneering3.2597 of 5 stars$4.05+17.4%$13.25+227.2%+242.6%$124.15MN/A-2.0760KYTXKyverna Therapeutics1.9932 of 5 stars$2.55-9.3%$18.50+625.5%-61.5%$121.44M$7.03M-0.7596UPXIUpexi2.5889 of 5 stars$3.26+2.2%$16.00+390.8%-39.5%$121.14M$16.56M0.00130Gap UpHigh Trading VolumePLXProtalix BioTherapeutics2.8014 of 5 stars$1.47-4.5%$15.00+920.4%+19.0%$117.02M$59.76M-11.31200Gap UpBHSTBioHarvest SciencesN/A$7.06+2.3%$13.67+93.6%N/A$113.33M$27.70M-14.12N/AHigh Trading Volume Related Companies and Tools Related Companies Fate Therapeutics Alternatives Caribou Biosciences Alternatives Cardiol Therapeutics Alternatives Korro Bio Alternatives Nkarta Alternatives Immuneering Alternatives Kyverna Therapeutics Alternatives Upexi Alternatives Protalix BioTherapeutics Alternatives BioHarvest Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKUR Stock Alerts